| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b data readout example | ficerafusp alfa (monotherapy and with pembrolizumab) 3L+ metastatic colorectal cancer (mCRC), RAS/BRAF wild type MSS | Phase 1b | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | |
Phase 1b data readout example | ficerafusp alfa (monotherapy and with pembrolizumab) 3L+ metastatic colorectal cancer (mCRC), RAS/BRAF wild type MSS | Phase 1b | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | |
Phase 1b data readout example | ficerafusp alfa (monotherapy and with pembrolizumab) 3L+ metastatic colorectal cancer (mCRC), RAS/BRAF wild type MSS | Phase 1b | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Bicara Therapeutics Inc.$28.91
-0.77 (-2.59%)
C 48Pipeline Score Overvalued Pharma · Commercial
Market Cap
1.42 B
EPS
-2.77
P/E Ratio
-
Value Trade
10.95 M
SEC Financials
Q1 2026Dilution Risk
Operating CF
-37.51 M
Total Assets
553.60 M
Total Liabilities
39.64 M
Equity
513.96 M
D/E Ratio
12,345
6.75 %
Week
-6.87 %
1 Month
40.87 %
3 Month
34.41 %
6 Month
-17.41 %
5 Year
-17.41 %
All Time
Cash Data
Cash Position
539.75 M
Monthly Burn
12.50 M
Runway
41.4 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
584.43 K
52 Week Range
8.48 - 24.25
% held by Insiders
42.84 %
% held by Institutions
78.01 %
Enterprise Value
886.15 M
Total Shares
65.70 M
Short %
19.95 %
Float Shares
50.72 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bicara Therapeutics Inc.
81Total events
7Upcoming
11Tier-1 (high impact)
2024 – 2027Coverage
Upcoming catalysts 7
2026-H2
T1Topline Readout
Data from Phase 1b expansion cohort evaluating ficerafusp alfa monotherapy and in combination with pembrolizumab in 3L+ mCRC
Event history 74
Q3 2026
◆Trial Initiationficerafusp alfaTrial
Initiate randomized study of ficerafusp alfa with pembrolizumab loading and Q3W maintenance regimen
1L R/M HPV-negative HNSCCsource ↗
Jun 2026
◆Oral Presentationficerafusp alfaPresentation
Present long-term follow-up data from Phase 1b at ASCO 2026
1L R/M HPV-negative HNSCCsource ↗
May 30, 2026
◆Oral Presentationficerafusp alfaPresentation
ASCO 2026 poster presentation: Sustained Depth and Durability of Response with TGF-β Trapping
1L R/M HPV-negative HNSCCsource ↗
May 29, 2026
◆Oral Presentationficerafusp alfaPresentation
Present long-term follow-up data from Phase 1b expansion cohorts at ASCO 2026
1L R/M HPV-negative HNSCCsource ↗
May 21, 2026
▲Full Resultsficerafusp alfaClinical Data
Extended follow-up data out to three years from Phase 1/1b study of ficerafusp alfa plus pembrolizumab
1L R/M HPV-negative HNSCCsource ↗
May 13, 2026
May 11, 2026
May 11, 2026
▲Publicationficerafusp alfaPresentation
Publication of Phase 1b expansion cohort results in Journal of Clinical Oncology
1L R/M HNSCCsource ↗
May 8, 2026
●Management ChangeCorporate
Bill Schelman promoted to CMO, David Raben transitions to Senior Executive Advisor
Q2 2026
◆Long Term Dataficerafusp alfaClinical Data
Long-term follow-up data from Phase 1b study of ficerafusp alfa + pembrolizumab
1L R/M HPV-negative HNSCCsource ↗
Drug Pipeline Intelligence
C48
Pipeline Score $365M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.3x
rNPV / MCap Top 72%
Micro Cap (rank 256 of 911)
Percentile RankBicara Therapeutics Inc. carries a moderate pipeline score (48/100), with $913M risk-adjusted pipeline value, led by Ficerafusp alfa in Squamous Cell Carcinoma of Head and Neck (SCCHN) (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ficerafusp alfa Small molecule | Squamous Cell Carcinoma of Head and Neck (SCCHN) | Phase 2 | NCT07529873 | 43% | $582M | NOT YET_RECRUITING | 131 | - | - | Dec 1, 2030 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ficerafusp alfa Breakthrough | recurrent/metastatic HPV-negative head and neck squamous cell carcinoma | Phase 1/1b | 2026-05-22 | overall survival rate: 31%; complete response rates: 750mg QW 13%, 1500mg QW 25%, 2000mg Q2W 30% Read More | Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC Read More | |
ficerafusp alfa Breakthrough | recurrent/metastatic HPV-negative head and neck squamous cell carcinoma | Phase 1/1b | 2026-05-22 | overall survival rate: 31%; complete response rates: 750mg QW 13%, 1500mg QW 25%, 2000mg Q2W 30% Read More | Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC Read More | |
ficerafusp alfa Breakthrough | recurrent/metastatic HPV-negative head and neck squamous cell carcinoma | Phase 1/1b | 2026-05-22 | overall survival rate: 31%; complete response rates: 750mg QW 13%, 1500mg QW 25%, 2000mg Q2W 30% Read More | Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BCAX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BCAX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BCAXBicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced the awarding of inducement grants to four new employees as part of their 2026 Inducement Plan. The grants include non-qualified stock options for a total of 191,425 shares at an exercise price of $28.91. These awards were approved by the company's compensation committee and are intended to attract talent in line with Nasdaq regulations.
Read more →BCAX▼ -5.2%on this news
ASCO 2026 Poster Presentation: A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: FORTIFI-HN01
The ASCO 2026 presentation discusses a phase 2/3 study evaluating ficerafusp alfa (BCA101) combined with pembrolizumab for treating PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma. This multicenter, randomized, double-blind trial aims to assess the efficacy of this treatment approach. The study represents a significant advancement in cancer therapy.
Read more →BCAX▼ -5.2%on this newsshared move
ASCO 2026 Poster Presentation: The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
The ASCO 2026 poster presentation discusses the impact of depth of response on long-term clinical outcomes from a phase 1/1b study involving ficerafusp alfa and pembrolizumab for treating first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma. The study's exploratory analyses from multiple expansion cohorts aim to provide insights into effective treatment strategies.
Read more →BCAX▼ -5.2%on this newsshared move
ASCO 2026 Poster Presentation: Sustained depth and durability of response with TGF-β trapping in recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): Long-term results from two expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab
The ASCO 2026 poster presentation highlighted the long-term results of a phase 1/1b study involving ficerafusp alfa combined with pembrolizumab for treating recurrent or metastatic HPV-negative head and neck squamous cell carcinoma. The study demonstrated sustained depth and durability of response, showcasing the potential of this combination therapy.
Read more →BCAXFicerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
Bicara Therapeutics announced promising three-year follow-up data for ficerafusp alfa in combination with pembrolizumab for first-line treatment of recurrent/metastatic HPV-negative head and neck squamous cell carcinoma. The study demonstrated a 31% overall survival rate, doubling the survival compared to standard treatments. The therapy showed deep and durable responses, supported by a favorable safety profile.
Read more →BCAX▼ -6.2%on this news
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced the awarding of a stock option grant to Christopher Sarchi, its new Chief Commercial Officer, as part of its 2026 Inducement Plan. The grant includes 282,240 shares with a vesting schedule tied to his continued employment. This move is part of Bicara's strategy to enhance its leadership as it develops bifunctional therapies for solid tumors.
Read more →BCAXBicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Bicara Therapeutics reported its Q1 2026 financial results, highlighting advancements in their pivotal trial for ficerafusp alfa in HPV-negative head and neck cancer. The company plans to initiate a new randomized study in Q3 2026, aiming for accelerated FDA approval. Additionally, executive leadership changes were announced to support commercialization efforts.
Read more →BCAXBicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. will report its first quarter 2026 financial results and business updates on May 11, 2026, at 8:30 AM ET. The company is focused on developing bifunctional therapies for solid tumors, particularly through its lead program, ficerafusp alfa. This therapy aims to improve patient outcomes in head and neck squamous cell carcinoma and other solid tumors.
Read more →BCAXBicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics has announced an inducement grant to a new employee as part of its 2026 Inducement Plan. The grant includes a non-qualified stock option for 44,175 shares at an exercise price of $20.50, with a structured vesting schedule. This action is in compliance with Nasdaq regulations and reflects Bicara's commitment to attracting talent in the biopharmaceutical sector.
Read more →BCAXBicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Bicara Therapeutics announced its fourth quarter and full year 2025 financial results, reporting significant progress in the development of its treatment ficerafusp alfa for HPV-negative head and neck cancer. The company initiated Phase 3 of the pivotal FORTIFI-HN01 trial with promising interim findings expected by mid-2027. It successfully raised $161.8 million to bolster its medical infrastructure and product development efforts. However, rising operational losses and R&D expenses signal financial risks that could affect future viability.
Read more →BCAXBicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. will report its fourth quarter and full year 2025 financial results on March 30, 2026, before the market opens. A conference call will be held at 8:30 AM ET to discuss these results and business updates. The company focuses on innovative bifunctional therapies for solid tumors, particularly with its lead program, ficerafusp alfa.
Read more →BCAXBicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Bicara Therapeutics announced the closing of its public offering, raising approximately $172.5 million through the sale of 8,581,250 shares and 2,200,000 pre-funded warrants. The offering was oversubscribed, reflecting strong investor interest. Proceeds from the offering will be utilized to enhance its medical infrastructure, support a regulatory filing for ficerafusp alfa, and further its clinical development programs. Bicara focuses on creating therapies for solid tumors, specifically targeting unmet needs in head and neck cancers.
Read more →BCAX▲ +7.8%on this newsshared move
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
Bicara Therapeutics has announced the pricing of a $150 million public offering of common stock and pre-funded warrants. The offering includes 7,175,000 shares priced at $16.00 each, with additional pre-funded warrants available. The company plans to use the proceeds to enhance its infrastructure and support the development of its lead therapy, ficerafusp alfa, for solid tumors. The offering is expected to close on February 26, 2026.
Read more →BCAX▲ +7.8%on this newsshared move
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
Bicara Therapeutics has announced a proposed public offering of $150 million in common stock, with an additional option for underwriters to purchase $22.5 million more. The funds will support the development and commercialization of ficerafusp alfa, a bifunctional therapy for solid tumors. The offering is contingent on market conditions and regulatory approvals.
Read more →BCAX▲ +5.9%on this newsshared move
Bicara Therapeutics to Participate in Upcoming Investor Conferences
Bicara Therapeutics Inc. announced its participation in several upcoming investor conferences, including fireside chats in Boston and Miami. The company aims to showcase its innovative bifunctional therapies, particularly ficerafusp alfa, a first-in-class treatment for solid tumors. Live webcasts of these events will be available on their website.
Read more →BCAX▼ -7.8%on this news
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced the awarding of inducement grants to two new employees under its 2026 Inducement Plan. The grants include non-qualified stock options for a total of 158,900 shares at an exercise price equal to the stock's closing price on February 2, 2026. These awards were approved by the company's compensation committee and are intended to incentivize employment with the firm.
Read more →BCAXBicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
Bicara Therapeutics announced the selection of 1500 mg ficerafusp alfa as the optimal dose for their Phase 3 FORTIFI-HN01 study in HPV-negative recurrent/metastatic head and neck squamous cell carcinoma. The company expects substantial enrollment in the trial by the end of 2026, aiming for an interim analysis in mid-2027. Bicara anticipates presenting significant data readouts related to ficerafusp alfa's clinical profile, and is preparing for a successful commercial launch amid growing market demands.
Read more →BCAXBicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
Bicara Therapeutics announced that CEO Claire Mazumdar will present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026. The presentation will focus on their lead program, ficerafusp alfa, a bifunctional antibody targeting solid tumors. A live webcast will be available, with a replay accessible afterward.
Read more →BCAXBicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
Bicara Therapeutics has presented preliminary Phase 1b data showing that 750mg of ficerafusp alfa combined with pembrolizumab demonstrates a 57% overall response rate in patients with HPV-negative recurrent/metastatic head and neck squamous cell carcinoma. The safety profile aligns with previous findings, and the company is on track to declare an optimal dose for the pivotal FORTIFI-HN01 study by the first quarter of 2026.
Read more →BCAX▼ -6.6%on this news
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
Bicara Therapeutics announced the publication of preliminary data from a Phase 1b expansion cohort studying ficerafusp alfa in combination with pembrolizumab for HPV-negative recurrent/metastatic head and neck squamous cell carcinoma. The data, which shows a high overall response rate, will be presented at the ESMO Asia Congress. The findings support the ongoing pivotal FORTIFI-HN01 trial and the potential for accelerated FDA approval.
Read more →BCAXBicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Bicara Therapeutics reported its third quarter 2025 financial results, highlighting the FDA's Breakthrough Therapy Designation for ficerafusp alfa in first-line HPV-negative R/M HNSCC. The company is focused on advancing its pivotal Phase 2/3 FORTIFI-HN01 trial and expects to present additional data at ESMO Asia 2025. Bicara maintains a robust financial position with around $408 million in cash.
Read more →BCAXBicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
Bicara Therapeutics announced that the FDA granted Breakthrough Therapy Designation to ficerafusp alfa for the first-line treatment of HPV-negative recurrent/metastatic head and neck squamous cell carcinoma. This designation highlights the urgent need for effective therapies in this patient population. Clinical trials have shown promising results, including a median duration of response of 21.7 months.
Read more →BCAXBicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Bicara Therapeutics has reported its second quarter 2025 financial results, highlighting a strong cash position of approximately $437 million, which is expected to sustain operations until mid-2029. Recent updates from the Phase 1/1b trial of ficerafusp alfa exhibited promising anti-tumor responses in patients with HPV-negative recurrent/metastatic head and neck squamous cell carcinoma. The company also confirmed ongoing enrollment in its pivotal Phase 2/3 trial, aiming to establish the drug's efficacy in this patient population. Further data from additional expansion cohorts are anticipated by early 2026.
Read more →BCAXBicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Bicara Therapeutics will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. The company focuses on developing bifunctional therapies for solid tumors, with its lead program, ficerafusp alfa, designed to enhance tumor penetration. The event will include a live webcast and an archived replay available afterward.
Read more →BCAX▲ +7%on this news· ran to +19% by day 3shared move
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
Bicara Therapeutics presented promising Phase 1/1b trial results for ficerafusp alfa combined with pembrolizumab in HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) at ASCO 2025. The treatment demonstrated a median duration of response of 21.7 months and a median overall survival of 21.3 months, with 80% of responders achieving significant tumor shrinkage. These results support the advancement of the pivotal Phase 2/3 trial, FORTIFI-HN01.
Read more →BCAX▼ -40.8%on this news
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
Bicara Therapeutics has published updated interim data from its Phase 1/1b trial of ficerafusp alfa combined with pembrolizumab for treating recurrent/metastatic head and neck squamous cell carcinoma. The data, presented at the 2025 ASCO Annual Meeting, indicates promising results, particularly in HPV-negative patients. A conference call is scheduled for June 1, 2025, to discuss the findings in detail.
Read more →BCAX▼ -8.1%on this news
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Bicara Therapeutics has announced its financial results for Q1 2025, highlighting its strong cash position of $462 million, which is expected to fund operations through the first half of 2029. The company is actively enrolling patients in pivotal trials for its drug ficerafusp alfa, targeting metastatic head and neck squamous cell carcinoma. Notable upcoming presentations at the 2025 ASCO Annual Meeting are anticipated to share updated data from ongoing clinical trials. Despite these positive developments, the company reported an increased net loss and higher research expenses compared to the previous year.
Read more →BCAXBicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
Bicara Therapeutics presented promising data on ficerafusp alfa at the AACR Annual Meeting 2025. This bifunctional antibody targets EGFR and TGF-β, showing potential in treating various solid tumors, including advanced cutaneous squamous cell carcinoma. The data suggest improved outcomes in patients with limited treatment options, highlighting the drug's capacity to enhance therapeutic durability.
Read more →BCAX▲ +12.2%on this newsshared move
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Bicara Therapeutics has announced that updated data from its ongoing Phase 1/1b trial of ficerafusp alfa for first-line recurrent/metastatic head and neck squamous cell carcinoma will be presented at the 2025 ASCO Annual Meeting. This first-in-class bifunctional antibody aims to provide substantial clinical benefits, particularly for HPV-negative patients who typically face worse outcomes. The clinical community's interest in the updated survival data further highlights the potential impact of ficerafusp alfa. The presentation is scheduled for June 1, 2025, at McCormick Place in Chicago, IL.
Read more →BCAXBicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Bicara Therapeutics reported its fourth quarter and full year 2024 financial results, highlighting significant advancements in its clinical trials and a strong cash position. The company has initiated patient dosing in the pivotal FORTIFI-HN01 trial for ficerafusp alfa in recurrent/metastatic head and neck cancer. Expected data updates from ongoing studies will be presented at major upcoming oncology meetings. Despite the encouraging developments, the company reported a substantial net loss for the year, reflecting increased operating costs.
Read more →BCAX▼ -5.6%on this newsshared move
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
Bicara Therapeutics Inc. has announced that three abstracts related to its lead product candidate, ficerafusp alfa, will be presented at the AACR Annual Meeting 2025. The presentations focus on various aspects of the drug, including its efficacy in treating metastatic cutaneous squamous cell carcinoma and its potential to reverse drug resistance in KRAS-G12C-mutated lung tumors. These findings are significant as ficerafusp alfa represents a novel approach in targeting established cancer pathways through dual blockade.
Read more →BCAXBicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Bicara Therapeutics Inc. will be presenting at the TD Cowen 45th Annual Health Care Conference on March 3, 2025. Claire Mazumdar, the CEO, will lead the presentation, highlighting the company's focus on transformative bifunctional therapies for solid tumors. A live webcast of the event will be available, along with a replay for those unable to attend.
Read more →BCAXBicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics has enrolled its first patients in the FORTIFI-HN01 clinical trial, assessing ficerafusp alfa combined with pembrolizumab for first-line recurrent/metastatic head and neck squamous cell carcinoma. This pivotal Phase 2/3 trial aims to recruit around 650 participants and evaluate primary endpoints including overall response rate and overall survival. Ficerafusp alfa is noted for its dual-targeting mechanism that may enhance anti-tumor activity. The trial is a crucial step in addressing the rising incidence of challenging head and neck cancers with low survival rates.
Read more →BCAXBicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
Bicara Therapeutics presented data from their Phase 1/1b trial of ficerafusp alfa combined with pembrolizumab for patients with second line or later squamous cancer of the anal canal at the 2025 ASCO GI Cancers Symposium. The preliminary results showed a 25% overall response rate and a 40.7% 12-month progression-free survival rate, indicating potential efficacy in a high-need patient population. The trial's findings suggest a promising role for ficerafusp alfa in enhancing treatment outcomes for squamous cell carcinomas. Safety profiles were tolerable, though some treatment-related adverse events were noted.
Read more →BCAX▼ -9.7%on this news
Fighting cancer with precision and power. Corporate Presentation | January 2025 2024 - 2025 Bicara Therapeutics Forward-Looking Statements This presentation contains forward-looking statements that involve substantial ri
Bicara Therapeutics is focusing on the development of ficerafusp alfa, a new treatment for recurrent/metastatic head and neck squamous cell carcinoma (HPV-negative). The company has initiated a Ph. 2/3 clinical trial and sees a significant market opportunity with a high unmet medical need. However, the presentation highlights various risks, including uncertainties in clinical trial outcomes and the need for adequate funding to support ongoing operations. Bicara's management team is experienced and aims to execute its strategic plans effectively.
Read more →BCAX▼ -7.3%on this news
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial publ
Bicara Therapeutics announced its financial results for Q3 2024, highlighting a successful upsized initial public offering that raised approximately $362 million. The company is well-positioned financially, with around $521 million in cash expected to sustain operations until 2029. Notably, Bicara is set to initiate the FORTIFI-HN01 trial, a pivotal Phase 2/3 study for ficerafusp alfa, aimed at treating recurrent and metastatic head and neck squamous cell carcinoma, following promising interim data.
Read more →BCAXBicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, will present at the Stifel 2024 Healthcare Conference in New York on November 19, 2024. The CEO, Claire Mazumdar, is expected to lead the presentation, highlighting the company's work on bifunctional therapies for solid tumors. A live webcast will be available on their website, with an archived version accessible for 90 days post-event.
Read more →BCAX▲ +8.5%on this news
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Bicara Therapeutics Inc. has announced the closing of its $362 million initial public offering, selling 20,125,000 shares at $18.00 each. The IPO included a full exercise of the underwriters' option to purchase additional shares. Bicara's shares started trading on the Nasdaq market on September 13, 2024. The company focuses on developing bifunctional therapies for patients with solid tumors, with its lead asset being ficerafusp alfa, targeting head and neck squamous cell carcinoma.
Read more →BCAXBicara Therapeutics Announces Pricing of Upsized Initial Public Offering
Bicara Therapeutics Inc. has announced the pricing of its upsized initial public offering, offering 17,500,000 shares at $18 each, expected to raise about $315 million. The company’s shares will begin trading on the Nasdaq Global Market under the ticker BCAX starting September 13, 2024. Bicara has also granted underwriters a 30-day option to purchase an additional 2,625,000 shares. The offering is set to close on September 16, 2024, pending customary conditions, with its lead therapy focusing on solid tumors.
Read more →Competitive Position
How BCAX ranks across every disease it competes inCompetitive Position is a premium feature
See how BCAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial